Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
· Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at week 26 · Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019) · 91 per cent of patients on pegcetacoplan were transfusion free compared to 22 per cent on standard of care (p<0.0001) · The safety profile of